Vicineum is a targeted fusion protein designed to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates. Vicineum is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC). To-date, Vicineum has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 17% complete response rate for patients with 12-month follow-ups in our ongoing Phase 3 trial.
理论上这个技术也算热点，但从股价上看如此低迷肯定有问题，有高手指教吗？
Vicineum is a targeted fusion protein designed to overcome the fundamental
efficacy and safety challenges inherent in existing antibody-drug conjugates. Vicineum is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive
bladder cancer (NMIBC). To-date, Vicineum has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 17% complete
response rate for patients with 12-month follow-ups in our ongoing Phase 3
trial.